AEON Biopharma (AEON) investor relations material

Company overview and business model

• Focuses on developing ABP-450 as a BOTOX® biosimilar for therapeutic indications, targeting accelerated and full-label U.S. market entry via a Biologics License Application under Section 351(k).

• Holds exclusive development and distribution rights for ABP-450 in the U.S., Canada, EU, UK, and select international territories.

• ABP-450 is manufactured by Daewoong Pharmaceutical in cGMP-compliant, FDA, Health Canada, and EMA-approved facilities.

• The global therapeutic botulinum toxin market is estimated at $3.3 billion, based on 2024 Botox segment revenues.

• Built a management team with deep experience in biopharmaceutical and botulinum toxin development and commercialization.

Financial performance and metrics

• KPMG LLP's audit report notes recurring losses from operations, net capital deficiency, and negative cash flows, raising substantial doubt about the company's ability to continue as a going concern.

• Financial statements for 2024 and 2023 are incorporated by reference, with the latest annual report filed March 24, 2025.

Use of proceeds and capital allocation

• Will not receive proceeds from the resale of shares by registered holders; proceeds from warrant exercises (if paid in cash) will go to the company.

• Registered holders bear underwriting discounts and commissions; company covers registration and related offering expenses.